Zinc binding agonist effect on the recognition of the β-amyloid (4-10) epitope by anti-β-amyloid antibodies

被引:19
作者
Zirah, S
Stefanescu, R
Manea, M
Tian, XD
Cecal, R
Kozin, SA
Debey, P
Rebuffat, S
Przybylski, M
机构
[1] Museum Natl Hist Nat, CNRS, UMR 5154, Dept Regulat Dev & Mol Divers, F-75231 Paris, France
[2] Natl Museum Nat Hist, CNRS, UMR 5153, Dept Regulat Dev & Mol Divers, F-75231 Paris 05, France
[3] Univ Konstanz, Dept Chem, Lab Analyt Chem & Biopolymer Struct Anal, D-78457 Constance, Germany
关键词
Alzheimer's disease; beta-amyloid peptide; zinc binding; epitope;
D O I
10.1016/j.bbrc.2004.06.150
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amyloid plaques associated to Alzheimer's disease present a high content of zinc ions. We previously showed that the N-terminal region of the amyloid peptide Abeta constitutes an autonomous zinc-binding domain. This region encompasses the previously identified epitope Abeta(4-10) targeted by antibodies capable to reduce amyloid deposition, but the influence of Abeta/Zn binding on the epitope recognition remains unknown. We demonstrate here the effect of Zn2+ ions on the recognition of peptides sharing the sequence of the Abeta N-terminal domain, by two monoclonal antibodies recognizing the beta-amyloid(4-10) epitope. The presence of Zn2+, but not of other cations, increased the recognition of the (1-16) peptide, while it was without effect on the recognition of the (1-10) peptide. These findings show a zinc-induced conformational change of the (1-16)-N-terminal region of All, which results in a better accessibility of the Abeta(4-10) epitope to the anti-Abeta antibodies, and suggest a role of zinc in epitope-based vaccination approaches. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:324 / 328
页数:5
相关论文
共 35 条
[1]  
Al-Shamkhani A, 1998, EUR J IMMUNOL, V28, P3291, DOI 10.1002/(SICI)1521-4141(199810)28:10<3291::AID-IMMU3291>3.0.CO
[2]  
2-E
[3]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[4]   RAPID INDUCTION OF ALZHEIMER A-BETA AMYLOID FORMATION BY ZINC [J].
BUSH, AI ;
PETTINGELL, WH ;
MULTHAUP, G ;
PARADIS, MD ;
VONSATTEL, JP ;
GUSELLA, JF ;
BEYREUTHER, K ;
MASTERS, CL ;
TANZI, RE .
SCIENCE, 1994, 265 (5177) :1464-1467
[5]   Metal complexing agents as therapies for Alzheimer's disease [J].
Bush, AI .
NEUROBIOLOGY OF AGING, 2002, 23 (06) :1031-1038
[6]   Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J].
Cherny, RA ;
Atwood, CS ;
Xilinas, ME ;
Gray, DN ;
Jones, WD ;
McLean, CA ;
Barnham, KJ ;
Volitakis, I ;
Fraser, FW ;
Kim, YS ;
Huang, XD ;
Goldstein, LE ;
Moir, RD ;
Lim, JT ;
Beyreuther, K ;
Zheng, H ;
Tanzi, RE ;
Masters, CL ;
Bush, AI .
NEURON, 2001, 30 (03) :665-676
[7]   DIVALENT METAL-IONS INDUCE CONFORMATIONAL CHANGE IN PURE, HUMAN WILD-TYPE P53 TUMOR-SUPPRESSOR PROTEIN [J].
COFFER, AI ;
KNOWLES, PP .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (02) :279-285
[8]   Zinc takes the center stage:: its paradoxical role in Alzheimer's disease [J].
Cuajungco, MP ;
Fagét, KY .
BRAIN RESEARCH REVIEWS, 2003, 41 (01) :44-56
[9]   AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED-CELLS DURING NORMAL METABOLISM [J].
HAASS, C ;
SCHLOSSMACHER, MG ;
HUNG, AY ;
VIGOPELFREY, C ;
MELLON, A ;
OSTASZEWSKI, BL ;
LIEBERBURG, I ;
KOO, EH ;
SCHENK, D ;
TEPLOW, DB ;
SELKOE, DJ .
NATURE, 1992, 359 (6393) :322-325
[10]   Transgenic mouse models of Alzheimer's disease [J].
Janus, C ;
Chishti, MA ;
Westaway, D .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2000, 1502 (01) :63-75